| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/neuroimage/HookerXSSCF08 |
| P356 | DOI | 10.1016/J.NEUROIMAGE.2008.03.003 |
| P932 | PMC publication ID | 2464626 |
| P698 | PubMed publication ID | 18434204 |
| P5875 | ResearchGate publication ID | 5329511 |
| P50 | author | Joanna S. Fowler | Q7472 |
| Jacob M. Hooker | Q52280455 | ||
| P2093 | author name string | Pauline Carter | |
| Youwen Xu | |||
| Colleen Shea | |||
| Wynne Schiffer | |||
| P2860 | cites work | Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist | Q24535736 |
| Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide | Q28263980 | ||
| Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization | Q33432985 | ||
| Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A. | Q34199279 | ||
| Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration | Q34269445 | ||
| Salvia divinorum and salvinorin A: new pharmacologic findings | Q34292784 | ||
| A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A. | Q34350014 | ||
| Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). | Q34538561 | ||
| Opioid receptors and legal highs: Salvia divinorum and Kratom | Q34747694 | ||
| Salvinorin A: from natural product to human therapeutics | Q36621232 | ||
| Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology. | Q36880395 | ||
| Kappa-opioid receptors and analgesia | Q37874600 | ||
| Pattern of use and subjective effects of Salvia divinorum among recreational users. | Q43842086 | ||
| 11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. | Q44348274 | ||
| Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates | Q44350288 | ||
| Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys | Q44350679 | ||
| Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals | Q48493698 | ||
| Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals | Q48719885 | ||
| Relationship between subjective effects of cocaine and dopamine transporter occupancy | Q48725518 | ||
| The preparation of a carbon-11 labelled neurohormone--[11C]melatonin | Q69816602 | ||
| Template images for nonhuman primate neuroimaging: 1. Baboon | Q74377941 | ||
| Unambiguous NMR spectral assignments of salvinorin A | Q79919819 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 1044-1050 | |
| P577 | publication date | 2008-03-15 | |
| P1433 | published in | NeuroImage | Q1981225 |
| P1476 | title | Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans | |
| P478 | volume | 41 |
| Q26776159 | A New Perspective on Delusional States - Evidence for Claustrum Involvement. |
| Q88257901 | A review of salvinorin analogs and their kappa-opioid receptor activity |
| Q35837572 | A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats |
| Q58102187 | Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence |
| Q47829315 | Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases. |
| Q48727079 | Analysis of the smoke of cigarettes containing Salvia divinorum. |
| Q35996706 | Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo |
| Q37286215 | Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen |
| Q34929007 | From divination to madness: features of acute intoxication with Salvia use |
| Q33918201 | Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. |
| Q36894509 | Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. |
| Q38550198 | Influence of Age on Salvia Divinorum Use: Results of an Internet Survey |
| Q38312641 | Kappa Opioid Receptor Agonist and Brain Ischemia |
| Q24643003 | Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways |
| Q30490227 | Metabolic changes in the rodent brain after acute administration of salvinorin A. |
| Q27300685 | Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans |
| Q37355904 | Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse |
| Q30467220 | Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A |
| Q33556502 | Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain |
| Q35269480 | Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity |
| Q38652778 | Salvia divinorum: An overview of the usage, misuse, and addiction processes |
| Q38116484 | Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug |
| Q64062550 | Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action |
| Q28481482 | Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets |
| Q34401390 | Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. |
| Q37349384 | Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence |
| Q34820974 | Salvinorin A decreases mortality and improves neurological outcome in a neonatal mouse hypoxia model |
| Q44343638 | Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors |
| Q36069379 | Salvinorin A produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel. |
| Q49629222 | Salvinorin A reduces neuropathic nociception in the insular cortex of the rat. |
| Q34302349 | Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. |
| Q26781580 | Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders |
| Q34083438 | Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A. |
| Q37507887 | The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats. |
| Q47878237 | The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects. |
| Q47977698 | The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice. |
| Q33835281 | The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects |
| Q67408888 | Ultrapotent chemogenetics for research and potential clinical applications. |
| Q37192749 | Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid |
Search more.